ANN ARBOR, Mich., Apr 23, 2008 (PrimeNewswire via COMTEX News Network) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM) will host two one-hour telephone Question & Answer sessions to provide further clarity on the proposal to amend the Company's Restated Articles of Incorporation to position the Company's Board of Directors to consider and execute a potential plan of action involving a reverse split of Aastrom's issued and outstanding common stock:

 What:   Aastrom Biosciences, Inc. Shareholder Question & Answer
         Sessions

 When:   Wednesday, April 23, 2008 @ 6:00 pm (EDT)
         Thursday, April 24, 2008 @ 12:00 pm (EDT)

 How:    Interested parties should call toll-free (877) 407-9205
         before the start of the Q&A Session to register and identify
         themselves as registrants of the "Aastrom Q&A Session."  Any
         registered caller on the toll-free line may ask the call
         operator for directions to be placed into the queue to ask a
         question.  If calling from outside the U.S., please use the
         international phone number (201) 689-8054.  This Q&A session
         will not be webcast, you must join the call to participate or
         listen.

Aastrom is a leading regenerative medicine company engaged in the development of autologous cell products for the repair or regeneration of human tissue. The Company's proprietary Tissue Repair Cell (TRC) technology involves the use of a patient's own cells to manufacture products to treat a range of chronic diseases and serious injuries affecting vascular, bone, cardiac and neural tissues. Aastrom's TRC-based products contain increased numbers of stem and early progenitor cells, produced from a small amount of bone marrow collected from the patient. The TRC technology platform has positioned Aastrom to advance multiple products into clinical development. Currently, the Company has a vascular regeneration product in clinical development for the treatment of critical limb ischemia (called the RESTORE-CLI trial), a bone regeneration product in Phase III development for the treatment of osteonecrosis of the femoral head (called the ON-CORE trial), a cardiac regeneration product in clinical development for dilated cardiomyopathy and a preclinical research program targeting unmet needs in neural health. Aastrom product candidates to treat osteonecrosis of the femoral head and dilated cardiomyopathy have been designated for orphan drug status by the FDA. For more information, visit Aastrom's website at www.aastrom.com. (astmc)

The Aastrom Biosciences, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3663

This news release was distributed by PrimeNewswire, www.primenewswire.com

SOURCE: Aastrom Biosciences, Inc.

Aastrom Biosciences, Inc.
          Investor Relations Department 
          (734) 930-5777 
          mail@aastrom.com

(C) Copyright 2008 PrimeNewswire, Inc. All rights reserved.

News Provided by COMTEX